Compare Natco Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA IPCA LABS NATCO PHARMA/
IPCA LABS
 
P/E (TTM) x 15.7 22.1 71.2% View Chart
P/BV x 3.1 4.3 72.0% View Chart
Dividend Yield % 1.4 0.1 1,317.7%  

Financials

 NATCO PHARMA   IPCA LABS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
IPCA LABS
Mar-18
NATCO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,080695 155.3%   
Low Rs671400 167.8%   
Sales per share (Unadj.) Rs592.1260.2 227.6%  
Earnings per share (Unadj.) Rs188.419.0 993.1%  
Cash flow per share (Unadj.) Rs206.333.1 624.2%  
Dividends per share (Unadj.) Rs8.251.00 825.0%  
Dividend yield (eoy) %0.90.2 516.0%  
Book value per share (Unadj.) Rs833.6213.0 391.3%  
Shares outstanding (eoy) m36.90126.20 29.2%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.52.1 70.3%   
Avg P/E ratio x4.628.9 16.1%  
P/CF ratio (eoy) x4.216.6 25.6%  
Price / Book Value ratio x1.12.6 40.9%  
Dividend payout %4.45.3 83.1%   
Avg Mkt Cap Rs m32,31169,120 46.7%   
No. of employees `0004.813.3 36.4%   
Total wages/salary Rs m3,2567,359 44.2%   
Avg. sales/employee Rs Th4,522.52,477.4 182.5%   
Avg. wages/employee Rs Th674.0555.2 121.4%   
Avg. net profit/employee Rs Th1,439.0180.6 796.6%   
INCOME DATA
Net Sales Rs m21,84832,836 66.5%  
Other income Rs m404418 96.7%   
Total revenues Rs m22,25233,254 66.9%   
Gross profit Rs m9,2844,505 206.1%  
Depreciation Rs m6621,777 37.2%   
Interest Rs m154240 64.1%   
Profit before tax Rs m8,8722,905 305.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,920511 375.7%   
Profit after tax Rs m6,9522,394 290.4%  
Gross profit margin %42.513.7 309.7%  
Effective tax rate %21.617.6 123.0%   
Net profit margin %31.87.3 436.4%  
BALANCE SHEET DATA
Current assets Rs m21,30719,455 109.5%   
Current liabilities Rs m5,92010,076 58.8%   
Net working cap to sales %70.428.6 246.6%  
Current ratio x3.61.9 186.4%  
Inventory Days Days7398 74.8%  
Debtors Days Days10767 159.1%  
Net fixed assets Rs m14,98620,260 74.0%   
Share capital Rs m369252 146.2%   
"Free" reserves Rs m30,35326,633 114.0%   
Net worth Rs m30,76026,886 114.4%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m37,15141,173 90.2%  
Interest coverage x58.613.1 447.6%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.8 73.7%   
Return on assets %19.16.4 298.9%  
Return on equity %22.68.9 253.8%  
Return on capital %29.310.8 272.6%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m10,32215,642 66.0%   
Fx outflow Rs m2,9784,884 61.0%   
Net fx Rs m7,34310,759 68.3%   
CASH FLOW
From Operations Rs m4,6363,411 135.9%  
From Investments Rs m-11,155-1,354 823.9%  
From Financial Activity Rs m6,509-1,304 -499.1%  
Net Cashflow Rs m-18753 -2.4%  

Share Holding

Indian Promoters % 52.0 45.9 113.4%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.4 68.8%  
FIIs % 16.6 25.3 65.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.4 149.4%  
Shareholders   25,395 36,892 68.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  PIRAMAL ENTERPRISES  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Oct 17, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - GLENMARK PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS